Multi-provincial Cohort for Hypertension (MUCH)

NCT03150888 | Unknown

• 1 other identifier: 2016YFC0900902
• Study Type: observational
• Target: 30,000
• Locations: 1 country
• Sites: 6

Brief Summary

The purpose of this study is to construct hypertension specialized cohort using uniform standards and specifications. This study timely collected multi-dimensional clinical information through electronic medical records, mobile health, data integration, informatics and computer modern techniques, linking self-reported data and big data platforms from different sources to timely obtain the incidence and mortality data, and integrating hypertension cohort samples and the associated clinical records systematically, in order to build a 30-thousand hypertension specialized cohort with fine phenotypic data and blood/urine samples, thus far to provide support for the development of precise medicine research and related industries.

Conditions

Hypertension

Outcome Measures

Primary Outcomes (1)

• Composite end point of major cardiovascular and cerebrovascular events

  Composite end point of major cardiovascular and cerebrovascular events

  From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year

Secondary Outcomes (5)

• New-onset of cardiovascular events

  From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year

• New-onset of stroke

  From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year

• Total death

  From date of enrollment until date of death from all cause, assessed up to 3 year

• Major bleeding

  From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year

• Atrial fibrillation

  From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year

Study Arms (2)

Hospital based hypertension cohort

Drug: Antihypertensive Agents; Other: Cardiovascular risk factors

Community based hypertension cohort

Drug: Antihypertensive Agents; Other: Cardiovascular risk factors

Interventions

Antihypertensive Agents DRUG

Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.

Community based hypertension cohort; Hospital based hypertension cohort

Cardiovascular risk factors OTHER

Different level of cardiovascular risk factors associated with genetics, environments and lifestyles.

Community based hypertension cohort; Hospital based hypertension cohort

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

primary care clinic, and community sample

You may qualify if:

• Clinical diagnosis of hypertension
• over 18 years old
• ti sign the informed consent

You may not qualify if:

• with life-threatening severe disease, such as severe tumor or AIDs
• pregnancy or lactating women,or plan to pregnant within half a year,
• with severe mental disorders
• participating in clinical trials

Sponsors & Collaborators

• Beijing Institute of Heart, Lung and Blood Vessel Diseases: lead
• Beijing Tsinghua Chang Gung Hospital: collaborator
• Beijing Tiantan Hospital: collaborator
• Ruijin Hospital: collaborator
• Nanfang Hospital, Southern Medical University: collaborator
• Southwest Hospital, China: collaborator

Study Sites (6)

Beijing Anzhen Hospital

Beijing, China

RECRUITING

Beijing Tiantan Hospital

Beijing, China

RECRUITING

Beijing Tsinghua Chang Gung Hospital

Beijing, China

RECRUITING

Southwest Hospital, China

Chongqing, China

RECRUITING

Nanfang Hospital of Southern Medical University

Guangzhou, China

ACTIVE NOT RECRUITING

Ruijin Hospital

Shanghai, China

ACTIVE NOT RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Serum, plasma, blood cell, urine and DNA

MeSH Terms

Conditions

Hypertension

Interventions

Antihypertensive Agents; Heart Disease Risk Factors

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Cardiovascular Agents; Therapeutic Uses; Pharmacologic Actions; Chemical Actions and Uses; Risk Factors; Risk; Probability; Statistics as Topic; Epidemiologic Methods; Investigative Techniques; Causality; Epidemiologic Factors; Quality of Health Care; Health Care Quality, Access, and Evaluation; Health Care Evaluation Mechanisms; Public Health; Environment and Public Health

Study Officials

• Jing Liu, MD,PhD

  Beijing Institute of Heart, Lung and Blood Vessel Diseases

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Yue Qi, PhD

CONTACT

+861064456324; qiyue_bjcn@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 5 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 4, 2017
• First Posted: May 12, 2017
• Study Start: July 3, 2017
• Primary Completion: December 1, 2020
• Study Completion: December 1, 2020
• Last Updated: January 22, 2020

Record last verified: 2020-01

Locations

CN (6)